New pharmacoeconomic option in uremic anemia management.
Savica
V
V
Mantovani
L
L
Santoro
D
D
Ricciardi
B
B
Bellinghieri
G
G
D000368:Aged; D000740:Anemia / Q000188:drug therapy* / Q000191:economics / Q000209:etiology; D003362:Cost-Benefit Analysis; D000068256:Darbepoetin alfa; D016527:Drug Costs; D004921:Erythropoietin / Q000031:analogs & derivatives* / Q000191:economics* / Q000627:therapeutic use; D005260:Female; D006397:Hematinics / Q000191:economics* / Q000627:therapeutic use; D006801:Humans; D008297:Male; D011994:Recombinant Proteins; D014511:Uremia / Q000150:complications*
D006397:Hematinics; D011994:Recombinant Proteins; D004921:Erythropoietin; D000068256:Darbepoetin alfa